This trial will Study a type of sarcoma defined metastatic soft-tissue sarcoma (STS). Participants will be treated with bexmarilimab, a CLEVER-1 antibody plus doxorubicin, a chemotherapy. The main purpose of the Study is to analyze the safety (to find out how safe or toxic a treatment is to appropriately manage the risks) and efficacy (to find out how effective a treatment is) of bexmarilimab combined with doxorubicin in participants who have STS.
Participant, or legal representative (if applicable), must be capable to understand the purpose of the Study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.
Female or male participants ≥ 18 years of age at the time of signing ICF.
Histologically documented metastatic STS with no more than 3 lines of treatment.
Participant has not received doxorubicin, but doxorubicin could be indicated for metastatic disease as per institutional guidelines.
Participation in another clinical trial, interventional or observational, until the Study's safety visit. Note: participation in retrospective studies or data analysis is allowed.
Treatment with approved or investigational cancer therapy within 14 days prior to initiation of Study drug.
Prior treatment with anthracyclines for localized or advanced disease.
Prior treatment with immunocheckpoint inhibitors for localized or advanced disease.
MedSIR
Lead sponsor
Faron Pharmaceuticals Ltd
Collaborator